Shares of Gilead Sciences Inc. fell sharply Friday as Wall Street viewed the drug developer's latest earnings report as sign that the company could be shifting to a more subdued level of growth as its HIV treatments saturate the market.
08/14/08 India: What Economic Reform?
08/14/08 Georgia: A Blow to U.S. Energy
08/14/08 Congress to Push Web Privacy
08/14/08 iPhone: More Fun Than Phone
08/20/08 Oil jumps, all eyes on supply report
08/20/08 Bargain hunters boost BJ's Wholesale
08/20/08 BP to test Georgia pipeline

